drugset / Trial / NCT03582007
Pivotal Study in Nosocomial Pneumonia Suspected or Confirmed to be Due to Pseudomonas
RandomizedParallel-groupSingle-blindTreatment
Summary
This is a phase 3, multicenter, open-label, sponsor blinded, randomized active-controlled, parallel group to investigate the efficacy, safety and tolerability of intravenous murepavadin given with ertapenem versus an anti-pseudomonal β-lactam based antibiotic in the treatment of nosocomial pneumonia in adult subjects
Timeline
- Start
- 2018-10-22
- Primary completion
- 2019-07-17
- Completion
- 2019-07-17
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Amoxicillin | Other / unclassified | — | — |
| Comparator | Meropenem | Small molecule | — | — |
| Subject | Murepavadin | Peptide | — | Intravenous |
| Background | Ertapenem | Small molecule | — | — |